Session Information
Session Type: Poster Session B
Session Time: 9:00AM-10:30AM
Background/Purpose: Major adverse cardiovascular events (MACE) and neoplasms are a concern in autoimmune diseases. RA and PsA are diseases where inflammation plays a key role in the development of the disease and the production of short- and long-term damage. TNF alpha plays a significant role in inflammation and the JAK/STAT signaling pathway is an important regulatory signaling cascades of intracellular processes, both used in the treatment of these conditions. It is extremely important to evaluate the effect of this treatments in long-term comorbidities associated with these diseases. The aim of this study is to provide real-world data on the influence of Anti-JAK, Anti-TNFa and cs-DMARDs treatment on cardiovascular events and non-melanoma cancer in patients with RA and PsA
Methods: Data from the BIOBADASAR 3.0 registry of patients diagnosed with RA and PsA (ACR-EULAR 2010 / CASPAR 2006) from June 2010 to May 2022. This data was extracted from patients treated with cs-DMARDs (control group), Anti-TNF alpha and JAK inhibitors. History of specific comorbidities and the appearance of AE were recorded. Event-free survival was evaluated by Kaplan Meier curves and the comparison between the different treatments was performed by Log Rank analysis. A p value less than 0.05 was considered statistically significant. We used R statistical package.
Results: Of a total of 6,209 patients, 4,817 (77.6%) with RA and 510 (8.2%) with PsA were studied.The overall frequency of non-melanoma cancer was 49 (2.1%) patients in the Anti-TNFa group, 6 (2.6%) in the Anti-JAK group, and 52 (2.4%) in the control group (p = 0.3). We observed a frequency of MACE of 48 (2.2%) in the Anti-TNFa group, 5 (2.37%) in the Anti-JAK group and 38 (1.84%) in the control group (p=0.6). The median time to the appearance of a MACE or cancer was 0.75 years for the APS group while in the RA group it was 3.25 years (p=0.21). Median MACE-free survival for Anti-JAK group was 0.5 years (CI95% 0.3 – NA), 1.8 years (CI95% 0.8 – 3.8) for Anti-TNFa group and it was 4.3 years (CI95% 3 – 6.5) for the control group (p=0.04).
Conclusion: In this study, we observed a higher MACE-free survival time in the group not exposed to biological drugs than in the Anti-TNFa group and lower in the Anti-JAK group with a statistically significant difference. However, these differences were not observed in the multivariate model adjusted for demographics data and comorbidities. We found no statistically significant difference in the appearance of the adverse events of interest between the RA and APS groups.
To cite this abstract in AMA style:
Brigante A, Quintana R, Isnardi C, Roberts K, Gomez G, Haye Salinas M, Soriano E, Pons-Estel G, De la Vega M, kerzberg O, Gamba J, Secco A, Citera G, Graf C, Savio V, Gallardo M, Aste N, Garcia M, Casado G, Gobbi C, Gomez G, Dapeña J, Berbotto G, Viola M, Rebak J, Dubinsky D, Saurit V, Petkovic I, Bertoli A, Catay E, Leoni C, Exeni I, Pons-Estel B, Paira S, Bovea Castelblanco G, De la Sota M, Pereira D, Medina G, Granel A, Larroude M, Alvarez A, Agüero S, Pisoni C, Sacnun M, Velozo E. Cardiovascular and Oncologic Outocomes of Anti-TNF Alfa and JAK Inhibitors in Patients with Rheumatoid and Psoriatic Arthritis. Real World Data and Insights of BIOBADASAR 3.0 Registry [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/cardiovascular-and-oncologic-outocomes-of-anti-tnf-alfa-and-jak-inhibitors-in-patients-with-rheumatoid-and-psoriatic-arthritis-real-world-data-and-insights-of-biobadasar-3-0-registry/. Accessed .« Back to ACR Convergence 2022
ACR Meeting Abstracts - https://acrabstracts.org/abstract/cardiovascular-and-oncologic-outocomes-of-anti-tnf-alfa-and-jak-inhibitors-in-patients-with-rheumatoid-and-psoriatic-arthritis-real-world-data-and-insights-of-biobadasar-3-0-registry/